Innovent Biologics, Inc.
IVBXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $5,953,094 | $5,469,597 | $3,952,291 | $3,504,538 |
| % Growth | 8.8% | 38.4% | 12.8% | – |
| Cost of Goods Sold | $1,353,562 | $1,317,359 | $1,094,389 | $1,025,086 |
| Gross Profit | $4,599,532 | $4,152,238 | $2,857,902 | $2,479,452 |
| % Margin | 77.3% | 75.9% | 72.3% | 70.7% |
| R&D Expenses | $1,008,799 | $1,281,642 | $1,399,432 | $1,304,739 |
| G&A Expenses | $442,111 | $418,245 | $319,801 | $381,890 |
| SG&A Expenses | $2,817,181 | $2,885,781 | $2,199,157 | $2,135,169 |
| Sales & Mktg Exp. | $2,375,070 | $2,467,536 | $1,879,356 | $1,753,279 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,825,980 | $4,167,423 | $3,598,589 | $3,439,908 |
| Operating Income | $773,552 | -$15,185 | -$740,687 | -$960,456 |
| % Margin | 13% | -0.3% | -18.7% | -27.4% |
| Other Income/Exp. Net | $123,565 | $329,149 | $348,102 | $72,154 |
| Pre-Tax Income | $897,117 | $313,964 | -$392,585 | -$888,302 |
| Tax Expense | $62,796 | $15,975 | $35 | $462 |
| Net Income | $834,321 | $297,989 | -$392,620 | -$888,764 |
| % Margin | 14% | 5.4% | -9.9% | -25.4% |
| EPS | 0.51 | 0.18 | -0.24 | -0.56 |
| % Growth | 183.3% | 175% | 57.1% | – |
| EPS Diluted | 0.49 | 0.18 | -0.24 | -0.56 |
| Weighted Avg Shares Out | 1,702,699 | 1,666,521 | 1,622,839 | 1,579,660 |
| Weighted Avg Shares Out Dil | 1,694,685 | 1,632,087 | 1,622,834 | 1,583,953 |
| Supplemental Information | – | – | – | – |
| Interest Income | $129,109 | $393,827 | $0 | $402,545 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $256,026 | $92,140 | $183,455 | $103,344 |
| EBITDA | $1,029,578 | -$231,413 | -$248,864 | -$741,753 |
| % Margin | 17.3% | -4.2% | -6.3% | -21.2% |